The FSHD Society is offering its first-ever CME-accredited masterclass on facioscapulohumeral muscular dystrophy (FSHD). This course, which will be held virtually on August 12, is of interest to any physician and allied health professional who sees adult and pediatric neuromuscular patients with undiagnosed FSHD.
The half-day course will cover diagnosis and management in adult and pediatric patients; updates on genetic and epigenetic testing; and molecular pathophysiology, current treatment strategies, and clinical trials. Attendees can earn up to 4.25 continuing medical education (CME) credits.
Although FSHD is one of the most common forms of muscular dystrophy, it is often under-diagnosed, and diagnosed patients don’t always benefit from the existing standards of care.
With the recent completion of a Phase 2b clinical trial showing promising disease-modifying results and several additional clinical trials gearing to launch in 2022, this course ensures that all clinicians caring for FSHD patients have access to the latest updates in diagnosis and management of their patients.
In developing this masterclass, the FSHD Society says it “aims to shorten the diagnostic journey (currently averaging 9 years) and improve care so that patients can fully benefit from future treatments,” a media release from FSHD Society notes.
Registrants from all geographic locations will be able to log in to the live webcast, which will include interactive sessions with ample time for questions and discussion. The course will be taught by a faculty that includes internationally recognized authorities in the field, including:
- Rabi Tawil, MD, University of Rochester
- Kathy Mathews, MD, University of Iowa
- Jacinda Sampson, MD PhD, Stanford University
- Katy Eichinger, DPT, University of Rochester
- Kiera Berggren, MA/CCC-SLP, Virginia Commonwealth University
- Bassem Elhassan, MD, MassGeneral Hospital
- Michelle Cao, MD, Stanford University
- Kent Drescher, PhD, Stanford VA (retired)
- Jeffrey Statland, MD, University of Kansas
- Doris Leung, MD PhD, Johns Hopkins University
“With several disease-modifying therapies currently in development, this is a time of unprecedented hope for people with FSHD. We want medical providers to be aware of these exciting prospects for treatment and to know how to connect their patients with FSHD to resources and studies so that they can fully benefit from these advances.”
— June Kinoshita, director of research and patient engagement at the FSHD Society
For more information and to register, visit FSHD Society. Registration is $50.
[Source(s): FSHD Society, PRWeb]